Free Trial

Galectin Therapeutics (GALT) SEC Filings & 10K Form

Galectin Therapeutics logo
$4.28 +0.03 (+0.71%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$4.26 -0.02 (-0.49%)
As of 08/29/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Galectin Therapeutics SEC Filings

DateFilerForm TypeView
08/14/2025
6:53 AM
Galectin Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2025
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/22/2025
6:36 AM
ELDRED KARY (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2025
9:38 AM
FREEMAN KEVIN D (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2025
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2025
11:01 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2025
5:25 PM
CZIRR JAMES C (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025
4:18 PM
CZIRR JAMES C (Reporting)
Galectin Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
05/15/2025
6:50 AM
Galectin Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/15/2025
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2025
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2025
6:50 AM
Galectin Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/31/2025
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2025
3:00 PM
Galectin Therapeutics (Issuer)
LEWIS JOEL (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2025
7:00 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/18/2025
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/30/2025
11:40 AM
Galectin Therapeutics (Issuer)
Shlevin Harold H. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/28/2025
7:00 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2025
3:03 PM
CARSON BENJAMIN SR (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:03 PM
ELDRED KARY (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:04 PM
FREEMAN KEVIN D (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:05 PM
Galectin Therapeutics (Issuer)
Jamil Khurram (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:06 PM
Galectin Therapeutics (Issuer)
LEWIS JOEL (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:06 PM
Galectin Therapeutics (Issuer)
OMENN GILBERT S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:07 PM
Galectin Therapeutics (Issuer)
Rubin Marc (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:01 PM
Galectin Therapeutics (Issuer)
OMENN GILBERT S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:02 PM
CALLICUTT JACK W (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
10:15 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
7:00 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/31/2024
6:45 AM
Galectin Therapeutics (Issuer)
Shlevin Harold H. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
7:20 AM
Galectin Therapeutics (Issuer)
Jamil Khurram (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
7:16 AM
Galectin Therapeutics (Issuer)
Zordani Richard A. Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
7:18 AM
CALLICUTT JACK W (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
7:18 AM
Galectin Therapeutics (Issuer)
LEWIS JOEL (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
7:02 AM
FREEMAN KEVIN D (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
7:07 AM
ELDRED KARY (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
3:17 PM
CALLICUTT JACK W (Reporting)
Galectin Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2024
3:18 PM
Galectin Therapeutics (Subject)
LEWIS JOEL (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2024
3:19 PM
Galectin Therapeutics (Subject)
Jamil Khurram (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/20/2024
6:50 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2024
7:03 AM
Galectin Therapeutics (Filer)
Form DEF 14A
Overnight moves = possibly bigger returns (Ad)

Here’s a chart everyone should see that dates back to 1993… As you can see, the top line shows the much bigger average market return from trading overnight… Versus the bottom line, which shows the more modest average return from trading during the day. Look at that gigantic difference! So if you prefer nice big overnight returns instead, I agree with you. That’s why I’ve designed a breakthrough trade to tap into that overnight trading frenzy. You can check that out right here. Obviously, I won’t make any reckless guarantees in the stock market, but… That eye-opening chart above is just the beginning of the benefits you’ll see to trading overnight. PLUS, you’ll also see what my #1 ranked asset is in the entire market… And what my “hands-off” stocks are that I wouldn’t touch with a 100-foot pole.tc pixel

Check out the breakthrough overnight trade before I take the video down.
12/03/2024
7:04 AM
Galectin Therapeutics (Filer)
Form DEFA14A
12/03/2024
7:05 AM
Galectin Therapeutics (Filer)
Form ARS
11/14/2024
6:55 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
7:00 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
6:51 AM
Galectin Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/23/2024
12:39 PM
ELDRED KARY (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
3:12 PM
FREEMAN KEVIN D (Reporting)
Galectin Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2024
3:10 PM
Boudes Pol F (Reporting)
Galectin Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
7:00 AM
Galectin Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:GALT) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners